Skip to main content

Advertisement

SpringerLink
Log in

Stem Cell Transplantation in Childhood Non-Hodgkin’s Lymphomas

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Despite the high cure rates achieved with intensified primary therapies for childhood non-Hodgkin’s lymphomas (NHL), the prognosis for children with relapsed or refractory disease is poor. Optimal treatment for this group remains a challenge. Dose intensification followed by stem cell transplantation has been used in these circumstances and may provide a curative treatment option for these patients, but the number of children treated using this approach is relatively small and its effectiveness has been difficult to judge. Moreover, the limited experience is insufficient to define the patient most likely to benefit from transplantation. Likewise, the selection of autologous or allogeneic transplantation and the optimal conditioning regimen are debated. We summarize the current experience for stem cell transplantation in childhood NHL and offer our recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. National Cancer Institute: Surveillance, Epidemiology and End Results (SEER) Program. Available at http://seer.cancer.gov/statistics/. Accessed June 30, 2010.

  2. Jaglowski SM, Linden E, Termuhlen AM, Flynn JM: Lymphoma in adolescents and young adults. Semin Oncol 2009, 36:381–418.

    Article  CAS  PubMed  Google Scholar 

  3. Patte C: Non-Hodgkin’s lymphomas in children [in French]. Rev Prat 1993, 43:1665–1668.

    CAS  PubMed  Google Scholar 

  4. Reiter A, Schrappe M, Parwaresch R, et al.: Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage—a report of the Berlin-Frankfurt-Münster group. J Clin Oncol 1995, 13:359–372.

    CAS  PubMed  Google Scholar 

  5. Majolino I, Pearce R, Taghipour G, Goldstone AH: Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin’s and non-Hodgkin’s lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry data. J Clin Oncol 1997, 15:509–517.

    CAS  PubMed  Google Scholar 

  6. Flohr T, Hess G, Kolbe K, et al.: Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002, 29:769–775.

    Article  CAS  PubMed  Google Scholar 

  7. Horwitz SM, Negrin RS, Blume KG, et al.: Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004, 103:777–783.

    Article  CAS  PubMed  Google Scholar 

  8. Khouri IF, Saliba RM, Hosing C, et al.: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2005, 23:2240–2247.

    Article  CAS  PubMed  Google Scholar 

  9. Armitage JO, Carbone PP, Connors JM, et al.: Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol 2003, 21:897–906.

    Article  PubMed  Google Scholar 

  10. Howe R, Micallef IN, Inwards DJ, et al.: Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2003, 32:317–324.

    Article  CAS  PubMed  Google Scholar 

  11. • Schmitz N, Dreger P, Glass B, Sureda A: Allogeneic transplantation in lymphoma: current status. Haematologica 2007, 92:1533–1548. This review summarizes the results of allo-HSCT after both myeloablative conditioning and reduced-intensity conditioning and discusses the evidence to support the existence of GvL effect.

    Article  PubMed  Google Scholar 

  12. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003, 31:667–678.

    Article  CAS  PubMed  Google Scholar 

  13. Russell NH, Byrne JL, Faulkner RD, et al.: Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:437–441.

    Article  CAS  PubMed  Google Scholar 

  14. Corradini P, Dodero A, Zallio F, et al.: Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphoma after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22:2172–2176.

    Article  PubMed  Google Scholar 

  15. Bollard CM, Gottschalk S, Leen AM, et al.: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007, 110:2838–2845.

    Article  CAS  PubMed  Google Scholar 

  16. Cho HI, Hong YS, Lee MA, et al.: Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol 2006, 83:66–73.

    Article  PubMed  Google Scholar 

  17. Cooper LJ, Al-Kadhimi Z, Serrano LM, et al.: Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005, 105:1622–1631.

    Article  CAS  PubMed  Google Scholar 

  18. Anderson JR, Jenkin RD, Wilson JF, et al.: Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood Non-Hodgkin’s lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 1993, 11:1024–1032.

    CAS  PubMed  Google Scholar 

  19. Patte C, Auperin A, Michon J, et al.: The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001, 97:3370–3379.

    Article  CAS  PubMed  Google Scholar 

  20. Patte C, Auperin A, Gerrard M, et al.: Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 2007, 109:2773–2780.

    CAS  PubMed  Google Scholar 

  21. Bowman WP, Shuster JJ, Cook B, et al.: Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol 1996, 14:1252–1261.

    CAS  PubMed  Google Scholar 

  22. Woessmann W, Seidemann K, Mann G, et al.: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group study NHL-BFM95. Blood 2005, 105:948–958.

    Article  CAS  PubMed  Google Scholar 

  23. Cairo MS, Gerrard M, Sposto R, et al.: Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007, 109:2736–2743.

    CAS  PubMed  Google Scholar 

  24. Mora J, Filippa DA, Qin J, Wollner N: Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial Sloan-Kettering Cancer Center. Cancer 2003, 98:1283–1291.

    Article  PubMed  Google Scholar 

  25. Reiter A, Schrappe M, Ludwig WD, et al.: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM Group report. Blood 2000, 95:416–421.

    CAS  PubMed  Google Scholar 

  26. Burkhardt B, Woessmann W, Zimmermann M, et al.: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006, 24:491–499.

    Article  PubMed  Google Scholar 

  27. Bergeron C, Celine S, Pacquement H, et al.: Childhood T cell lymphoblastic lymphoma (TLL) results of the SFOP LMT96 strategy [abstract 101]. Pediatr Blood Cancer 2006, 46(7):867.

    Google Scholar 

  28. Seidemann K, Tiemann M, Schrappe M, et al.: Short-pulse B-non-Hodgkin lymphoma–type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group trial NHL-BFM 90. Blood 2001, 97:3699–3706.

    Article  CAS  PubMed  Google Scholar 

  29. Rosolen A, Pillon M, Garaventa A, et al.: Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 Protocol. Cancer 2005, 104:2133–2140.

    Article  CAS  PubMed  Google Scholar 

  30. Burkhardt B, Reiter A, Lang P, et al.: Relapse in pediatric pts with T-cell lymphoblastic lymphoma: clinical characteristics and outcome in the BFM Group [abstract 25]. Pediatr Blood Cancer 2006, 46(7):842.

    Google Scholar 

  31. Ladenstein R, Pearce R, Hartmann O, et al.: High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt’s lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997, 90:2921–2930.

    CAS  PubMed  Google Scholar 

  32. Baker KS, Gordon BG, Gross TG, et al.: Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. J Clin Oncol 1999, 17:825–831.

    CAS  PubMed  Google Scholar 

  33. • Gross TG, Hale GA, He W, et al.: Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010, 16:223–230. These registry data provide the largest experience for both auto-SCT and allo-SCT across the spectrum of pediatric non-Hodgkin’s lymphoma.

    Article  PubMed  Google Scholar 

  34. Harris NL, Jaffe ES, Diebold J, et al.: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999, 10:1419–1432.

    Article  CAS  PubMed  Google Scholar 

  35. Savage KJ, Monti S, Kutok JL, et al.: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102:3871–3879.

    Article  CAS  PubMed  Google Scholar 

  36. Bureo E, Ortega JJ, Munoz A, et al.: Bone marrow transplantation in 46 pediatric patients with non-Hodgkin’s lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant 1995, 15:353–359.

    CAS  PubMed  Google Scholar 

  37. van Imhoff GW, van der Holt B, MacKenzie MA, et al.: Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005, 19:945–952.

    Article  PubMed  Google Scholar 

  38. Song KW, Barnett MJ, Gascoyne RD, et al.: Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol 2006, 133:634–637.

    Article  PubMed  Google Scholar 

  39. Won SC, Han JW, Kwon SY, et al.: Autologous peripheral blood stem cell transplantation in children with non-Hodgkin’s lymphoma: a report from the Korean Society Of Pediatric Hematology-Oncology. Ann Hematol 2006, 85:787–794.

    Article  PubMed  Google Scholar 

  40. Burkhardt B, Zimmermann M, Oschlies I, et al.: The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005, 131:39–49.

    Article  PubMed  Google Scholar 

  41. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235–242.

    Article  CAS  PubMed  Google Scholar 

  42. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503–511.

    Article  CAS  PubMed  Google Scholar 

  43. Oschlies I, Klapper W, Zimmermann M, et al.: Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Münster) multicenter trial. Blood 2006, 107:4047–4052.

    Article  CAS  PubMed  Google Scholar 

  44. Miles RR, Raphael M, McCarthy K, et al.: Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) International Study Group. Pediatr Blood Cancer 2008, 51:369–374.

    Article  PubMed  Google Scholar 

  45. Pfreundschuh M, Trumper L, Osterborg A, et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) group. Lancet Oncol 2006, 7:379–391.

    Article  CAS  PubMed  Google Scholar 

  46. Habermann TM, Weller EA, Morrison VA, et al.: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121–3127.

    Article  CAS  PubMed  Google Scholar 

  47. Saito B, Shiozawa E, Usui T, et al.: Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. Leukemia 2007, 21:2563–2566.

    Article  CAS  PubMed  Google Scholar 

  48. Savage KJ, Al-Rajhi N, Voss N, et al.: Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006, 17:123–130.

    Article  CAS  PubMed  Google Scholar 

  49. Vellenga E, van Putten WL, van ’t Veer MB, et al.: Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive cCD20+ NHL: a prospective randomized HOVON trial. Blood 2008, 111:537–543.

    Article  CAS  PubMed  Google Scholar 

  50. Thomas DA, O’Brien S, Cortes J, et al.: Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004, 104:1624–1630.

    Article  CAS  PubMed  Google Scholar 

  51. Abromowitch M, Termuhlen A, Chang M, et al.: High-dose methotrexate and early intensification of therapy do not improve 3 year EFS in children and adolescents with disseminated lymphoblastic lymphoma. Results of the randomized arms of COG A5971 [poster]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 3610.

  52. •• Reiter A: Diagnosis and treatment of childhood non-Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007:285–296. This article summarizes the results of recent multicenter studies on childhood lymphomas and discusses new treatment options for children with relapsed disease.

  53. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol 2009, 144:24–40.

    Article  PubMed  Google Scholar 

  54. Burkhardt B, Reiter A, Landmann E, et al.: Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster Group. J Clin Oncol 2009, 27:3363–3369.

    Article  PubMed  Google Scholar 

  55. Sweetenham JW, Santini G, Qian W, et al.: High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001, 19:2927–2936.

    CAS  PubMed  Google Scholar 

  56. Levine JE, Harris RE, Loberiza FR Jr, et al.: A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003, 101:2476–2482.

    Article  CAS  PubMed  Google Scholar 

  57. Le Deley MC, Reiter A, Williams D, et al.: Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European Intergroup Study. Blood 2008, 111:1560–1566.

    Article  PubMed  Google Scholar 

  58. Liang X, Meech SJ, Odom LF, et al.: Assessment of t(2, 5)(p23, q35) translocation and variants in pediatric ALK + anaplastic large cell lymphoma. Am J Clin Pathol 2004, 121:496–506.

    Article  PubMed  Google Scholar 

  59. Falini B: Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol 2001, 114:741–760.

    Article  CAS  PubMed  Google Scholar 

  60. Hutchison RE, Banki K, Shuster JJ, et al.: Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood. Ann Oncol 1997, 8(Suppl 1):37–42.

    Article  PubMed  Google Scholar 

  61. Gascoyne RD, Aoun P, Wu D, et al.: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999, 93:3913–3921.

    CAS  PubMed  Google Scholar 

  62. Reiter A, Schrappe M, Tiemann M, et al.: Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Münster Group studies. J Clin Oncol 1994, 12:899–908.

    CAS  PubMed  Google Scholar 

  63. Brugieres L, Quartier P, Le Deley MC, et al.: Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children: a report from the French Society of Pediatric Oncology. Ann Oncol 2000, 11:53–58.

    Article  CAS  PubMed  Google Scholar 

  64. Brugieres L, Pacquement H, Le Deley MC, et al.: Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol 2009, 27:5056–5061.

    Article  CAS  PubMed  Google Scholar 

  65. Fanin R, Ruiz de Elvira MC, Sperotto A, et al.: Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999, 23:437–442.

    Article  CAS  PubMed  Google Scholar 

  66. Mori T, Takimoto T, Katano N, et al.: Recurrent childhood anaplastic large cell lymphoma: A retrospective analysis of registered cases in Japan. Br J Haematol 2006, 132:594–597.

    Article  PubMed  Google Scholar 

  67. Woessmann W, Peters C, Lenhard M, et al.: Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents—a Berlin-Frankfurt-Münster Group report. Br J Haematol 2006, 133:176–182.

    Article  PubMed  Google Scholar 

  68. Woessmann W, Lenhard M, Burkhardt B, et al.: Salvage strategy for anaplastic large cell lymphoma in children: prognostic impact of time to relapse and CD3 reactivity [abstract 090]. Ann Oncol 2005, 16(suppl 5):v62.

    Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Texas Children’s Cancer Center, Center for Cell and Gene Therapy, 1102 Bates Street, Houston, TX, 77030, USA

    Fatma V. Okur & Robert Krance

Authors
  1. Fatma V. Okur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Krance
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fatma V. Okur.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okur, F.V., Krance, R. Stem Cell Transplantation in Childhood Non-Hodgkin’s Lymphomas. Curr Hematol Malig Rep 5, 192–199 (2010). https://doi.org/10.1007/s11899-010-0059-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-010-0059-5

Keywords

Search

Navigation